Biomedical Engineering Reference
In-Depth Information
Table 3
Results from venlafaxine study
Venlafaxine daily
dose (mg)
Patient
Min.
Max.
Mean
%CV
Min.
Max.
Mean
%CV
r
2
1
150
C
PL
74.7
125.7
97.3
21.8
R
OF/PL
2.4
5.5
4.0
30.9
0.631
C
PL-FF
39.0
134.1
84.9
53.0
R
OF/PL-FF
4.0
6.8
5.0
25.6
0.848
C
OF
182.5
531.2
397.7
39.6
2
150
C
PL
52.4
72.6
60.6
14.8
R
OF/PL
4.2
7.7
5.5
28.3
0.239
C
PL-FF
37.2
46.2
42.1
11.2
R
OF/PL-FF
6.5
8.7
7.7
12.9
0.332
C
OF
285.6
404.7
323.9
16.8
3
150
C
PL
25.1
44.9
33.8
24.7
R
OF/PL
2.3
8.6
4.3
69.6
0.027
C
PL-FF
6.8
14.0
11.2
27.7
R
OF/PL-FF
7.3
23.3
12.5
58.8
0.101
C
OF
58.8
265.0
140.9
63.1
4
75
C
PL
40.0
51.1
44.8
11.6
R
OF/PL
3.6
6.3
4.8
24.2
0.245
C
PL-FF
13.8
20.9
17.0
17.3
R
OF/PL-FF
6.9
16.9
13.1
33.6
0.252
C
OF
144.4
289.2
215.7
27.4
5
75
C
PL
17.5
25.7
22.5
15.6
R
OF/PL
3.4
9.0
6.9
35.7
0.178
C
PL-FF
8.3
16.6
12.4
37.7
R
OF/PL-FF
4.9
25.0
14.4
57.2
0.028
C
OF
82.1 214.7 156.8 41.6
Venlafaxine concentrations in plasma (
C
PL
), in the plasmatic free fraction (
C
PL-FF
) and in oral fluid (
C
OF
), plasmatic or plasmatic free fraction/oral fluid concen-
tration ratios (
R
OF/PL
or
R
OF/PL-FF
, respectively) and the calculated coefficients of determination (
r
2
) for
C
OF
vs.
C
PL
or
C
PL-FF
(
n
= 4) (
Source
: From de Castro A et al.
(2008) J Pharm Biomed Anal. 48:183. With permission)
